Antonio Ramos-Montoya

6PUBLICATIONS
31CO-AUTHORS
Biomolecular modelling and designCheminformatics and quantitative structure-activity relationshipsMolecular targetsRadiation therapyTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 09, 2026
Proteome-guided drug discovery maps and mitigates therapeutic degrader toxicity.

|Jan 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.

James S Scott, Laura Evans, Peter C Astles

|Feb 12, 2022
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.

Alessia Anastasia, Giulia Dellavedova, Antonio Ramos-Montoya

|May 20, 2021
Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.

Kyoko Nakamura, Ankur Karmokar, Paul M Farrington

|Mar 31, 2021
Macrophage Activation Status Rather than Repolarization Is Associated with Enhanced Checkpoint Activity in Combination with PI3Kγ Inhibition.

Larissa S Carnevalli, Molly A Taylor, Matthew King

|Nov 09, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.

Jacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada

Pageof 1

Frequent Collaborators

3 joint publications

Elaine B Cadogan

2 joint publications

Monica Rodrigo-Brenni

2 joint publications

Charlene Fallan

1 joint publications

Sophie E Willis